Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 16/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 5/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 0.83 |
| ▸ | ABL1 | P00519 | 1/20 | 0.83 |
| ▸ | BCR | P11274 | 1/20 | 0.83 |
| ▸ | CLK1 | P49759 | 1/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.72 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4456469 | 1.00 | FLT3 (1.00) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL2230377 | 0.91 | FLT3 (1.00) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL31060426 | 0.88 | FLT3 (1.00) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL370573 | 0.88 | FLT3 (1.00) | FLT3PDGFRBPDGFRAKITABL1 | |
| Methane SCHEMBL22343918 | 0.86 | FLT3 (0.96) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL31060211 | 0.82 | FLT3 (1.00) | FLT3PDGFRBPDGFRA | |
| SCHEMBL20742916 | 0.82 | FLT3 (0.81) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL61386 | 0.79 | SMAD3 (1.00) | FLT3PDGFRBPDGFRAKITABL1 | |
| SCHEMBL6865103 | 0.78 | FLT3 (1.00) | FLT3PDGFRBPDGFRA | |
| SCHEMBL2732420 | 0.77 | FLT3 (0.73) | FLT3PDGFRBPDGFRAKITABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2025015263-A2 | TREATING MYELOID DISORDERS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-01-16 | — | — | WO | claimed |
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025015263-A2 | TREATING MYELOID DISORDERS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240100018-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | CEDARS-SINAI MEDICAL CENTER | 2024-03-28 | — | — | US | disclosed |